-
Something wrong with this record ?
Capillary electrophoresis integrated immobilized enzyme reactor for kinetic and inhibition assays of β-secretase as the Alzheimer's disease drug target
J. Schejbal, Š. Šefraná, R. Řemínek, Z. Glatz,
Language English Country Germany
Document type Journal Article
Grant support
Czech Science Foundation
- MeSH
- Alzheimer Disease drug therapy metabolism MeSH
- Bioreactors * MeSH
- Electrophoresis, Capillary MeSH
- Enzymes, Immobilized antagonists & inhibitors chemistry metabolism MeSH
- HEK293 Cells MeSH
- Enzyme Inhibitors chemistry pharmacology MeSH
- Kinetics MeSH
- Humans MeSH
- Peptides chemistry pharmacology MeSH
- Amyloid Precursor Protein Secretases antagonists & inhibitors chemistry metabolism MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
Capillary electrophoresis integrated immobilized enzyme reactors are becoming an increasingly popular alternative for enzyme kinetic and inhibition assays thanks to their unique set of features including cost effectiveness, repeated use of the enzyme, minuscule sample consumption, rapid analysis time and easy automation. In this work we present the development and application of a capillary electrophoresis integrated immobilized enzyme reactor based on magnetic particles for kinetic and inhibition studies of β-secretase, a key enzyme in the development of Alzheimer's disease and a promising drug target. We document the optimization of the immobilization procedure, characterization of immobilized β-secretase, optimization of a mutually compatible incubation protocol and separation method as well as the production of the capillary electrophoresis integrated immobilized enzyme reactor. The applicability of the capillary electrophoresis integrated immobilized enzyme reactor was demonstrated by kinetic assay with an unlabelled substrate and by inhibition assays using three structurally different reference inhibitors. The resulting kinetic and inhibition parameters clearly support the applicability of the herein presented method as well as document the fundamental phenomena which need to be taken in account when comparing the results to other methods.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19027888
- 003
- CZ-PrNML
- 005
- 20190823094620.0
- 007
- ta
- 008
- 190813s2019 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/jssc.201800947 $2 doi
- 035 __
- $a (PubMed)30663871
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Schejbal, Jan $u Department of Biochemistry, Faculty of Science, Masaryk University, Brno, Czech Republic.
- 245 10
- $a Capillary electrophoresis integrated immobilized enzyme reactor for kinetic and inhibition assays of β-secretase as the Alzheimer's disease drug target / $c J. Schejbal, Š. Šefraná, R. Řemínek, Z. Glatz,
- 520 9_
- $a Capillary electrophoresis integrated immobilized enzyme reactors are becoming an increasingly popular alternative for enzyme kinetic and inhibition assays thanks to their unique set of features including cost effectiveness, repeated use of the enzyme, minuscule sample consumption, rapid analysis time and easy automation. In this work we present the development and application of a capillary electrophoresis integrated immobilized enzyme reactor based on magnetic particles for kinetic and inhibition studies of β-secretase, a key enzyme in the development of Alzheimer's disease and a promising drug target. We document the optimization of the immobilization procedure, characterization of immobilized β-secretase, optimization of a mutually compatible incubation protocol and separation method as well as the production of the capillary electrophoresis integrated immobilized enzyme reactor. The applicability of the capillary electrophoresis integrated immobilized enzyme reactor was demonstrated by kinetic assay with an unlabelled substrate and by inhibition assays using three structurally different reference inhibitors. The resulting kinetic and inhibition parameters clearly support the applicability of the herein presented method as well as document the fundamental phenomena which need to be taken in account when comparing the results to other methods.
- 650 _2
- $a Alzheimerova nemoc $x farmakoterapie $x metabolismus $7 D000544
- 650 _2
- $a sekretasy $x antagonisté a inhibitory $x chemie $x metabolismus $7 D053829
- 650 12
- $a bioreaktory $7 D019149
- 650 _2
- $a elektroforéza kapilární $7 D019075
- 650 _2
- $a inhibitory enzymů $x chemie $x farmakologie $7 D004791
- 650 _2
- $a enzymy imobilizované $x antagonisté a inhibitory $x chemie $x metabolismus $7 D004800
- 650 _2
- $a HEK293 buňky $7 D057809
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kinetika $7 D007700
- 650 _2
- $a peptidy $x chemie $x farmakologie $7 D010455
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Šefraná, Šárka $u Department of Biochemistry, Faculty of Science, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Řemínek, Roman $u Department of Biochemistry, Faculty of Science, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Glatz, Zdeněk $u Department of Biochemistry, Faculty of Science, Masaryk University, Brno, Czech Republic.
- 773 0_
- $w MED00006463 $t Journal of separation science $x 1615-9314 $g Roč. 42, č. 5 (2019), s. 1067-1076
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30663871 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190813 $b ABA008
- 991 __
- $a 20190823094834 $b ABA008
- 999 __
- $a ok $b bmc $g 1433037 $s 1066348
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 42 $c 5 $d 1067-1076 $e 20190204 $i 1615-9314 $m Journal of separation science $n J Sep Sci $x MED00006463
- GRA __
- $p Czech Science Foundation
- LZP __
- $a Pubmed-20190813